UNSPSC 51262913: Prenalterol hydrochloride

This classification denotes an adrenergic beta-1 receptor agonist C12H19NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6VH18LCQ8, chemically known as phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, hydrochloride, (s)-, but more generally known as prenalterol hydrochloride, which bears US NIH Compound Identifier 43590. European Medicines Agency schedules Prenalterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04029MIG.

Most nations, for tariff and trade purposes, schedule prenalterol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PRENALTEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NC[C@@H](COC1CCC(CC1)O)O.CL.

UNSPSC 51262913 Prenalterol hydrochloride is a Commodity code that, based on recent state and local solicitation activity, does not describe the work actually being procured under it. Seminole County, Florida's IFB60459723LAS solicitation, posted June 30, 2026 with a July 26, 2023 response deadline, seeks procurement of naloxone and safe drug deactivation systems — neither of which aligns with prenalterol hydrochloride, a cardiac stimulant pharmaceutical distinct in therapeutic class and application. The mismatch suggests either a coding error in the county's procurement system or a misalignment between the UNSPSC designation and the goods being acquired. State and local procurement offices occasionally apply incorrect codes during notice posting, particularly when pharmaceutical or medical supply categories overlap or when commodity identifiers are not validated against actual line-item descriptions before publication.

The Seminole County opportunity represents the only recent state-local activity visible under this code; no other jurisdictions have posted solicitations for prenalterol hydrochloride or closely related products during the review period. Absent additional opportunities that correctly reflect the code's therapeutic scope, there is insufficient activity to characterize issuing-body concentration, geographic spread, or typical procurement patterns. Firms targeting this Commodity code should verify the actual pharmaceutical scope of any state or local RFP, RFQ, IFB, or ITB notice before pursuing — the code itself may not reliably predict what is actually being bought or which product specifications will appear in the statement of work.